KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
$523.61M
Mr. Thomas Andrew Crockett M.B.A.
105.00
Cambridge, MA
Apr 09, 2015
-3.01
$-3.57
1.42
8.55
-11,755.47%
-3.62
-0.20
2.97
447.97
8.55
-70.82%
-97.37%
Similar stocks (15)
Cytokinetics, Incorporated
CYTK
Crinetics Pharmaceuticals, Inc.
CRNX
Edgewise Therapeutics, Inc.
EWTX
Dyne Therapeutics, Inc.
DYN
Mirum Pharmaceuticals, Inc.
MIRM
Kura Oncology, Inc.
KURA
Cogent Biosciences, Inc.
COGT
Cullinan Oncology, Inc.
CGEM
Replimune Group, Inc.
REPL
Larimar Therapeutics, Inc.
LRMR
Mersana Therapeutics, Inc.
MRSN
Nuvectis Pharma, Inc.
NVCT
Gossamer Bio, Inc.
GOSS
Kronos Bio, Inc.
KRON
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (16)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.39%
iShares Micro-Cap ETF
IWC
0.09759%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.046%
Direxion Daily S&P Biotech Bull 3X Shares
LABU
0.0427584669%
iShares Biotechnology ETF
IBB
0.03138%
iShares Russell 2000 Growth ETF
IWO
0.02909%
iShares Russell 2000 ETF
IWM
0.01441%
ProShares Ultra Nasdaq Biotechnology
BIB
0.013713015795510769%
Dimensional U.S. Small Cap ETF
DFAS
0.00881113%
Dimensional US Sustainability Core 1 ETF
DFSU
0.00272461%
ProShares Hedge Replication ETF
HDG
0.0023591030588969507%
Dimensional U.S. Core Equity 2 ETF
DFAC
0.0021260999999999997%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
7.8e-4%
Dimensional US Core Equity Market ETF
DFAU
6.7535e-4%
iShares Russell 3000 ETF
IWV
4.6e-4%
Dimensional U.S. Equity ETF
DFUS
4.4686e-4%
Similar stocks (15)
Cytokinetics, Incorporated
CYTK
Crinetics Pharmaceuticals, Inc.
CRNX
Edgewise Therapeutics, Inc.
EWTX
Dyne Therapeutics, Inc.
DYN
Mirum Pharmaceuticals, Inc.
MIRM
Kura Oncology, Inc.
KURA
Cogent Biosciences, Inc.
COGT
Cullinan Oncology, Inc.
CGEM
Replimune Group, Inc.
REPL
Larimar Therapeutics, Inc.
LRMR
Mersana Therapeutics, Inc.
MRSN
Nuvectis Pharma, Inc.
NVCT
Gossamer Bio, Inc.
GOSS
Kronos Bio, Inc.
KRON
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (16)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.39%
iShares Micro-Cap ETF
IWC
0.09759%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.046%
Direxion Daily S&P Biotech Bull 3X Shares
LABU
0.0427584669%
iShares Biotechnology ETF
IBB
0.03138%
iShares Russell 2000 Growth ETF
IWO
0.02909%
iShares Russell 2000 ETF
IWM
0.01441%
ProShares Ultra Nasdaq Biotechnology
BIB
0.013713015795510769%
Dimensional U.S. Small Cap ETF
DFAS
0.00881113%
Dimensional US Sustainability Core 1 ETF
DFSU
0.00272461%
ProShares Hedge Replication ETF
HDG
0.0023591030588969507%
Dimensional U.S. Core Equity 2 ETF
DFAC
0.0021260999999999997%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
7.8e-4%
Dimensional US Core Equity Market ETF
DFAU
6.7535e-4%
iShares Russell 3000 ETF
IWV
4.6e-4%
Dimensional U.S. Equity ETF
DFUS
4.4686e-4%